INMB Investor Presentation 2023 - Innate Immune Therapeutics

Inmunitas Therapeutics (INMB) investor presentation detailing two therapeutic platforms—XPro™ for CNS disorders and INKmune™ for cancer—designed to repair innate immune dysfunction. The company features multiple clinical-stage programs with significant insider ownership and a market cap of approximately $145M as of May 2023.